U. Mey, F. Hitz, A. Lohri, S. Pederiva, C. Taverna, A. Tzankov, O. Meier, K. Yeow, C. Renner. 2012. Diagnosis and treatment of diffuse large B-cell lymphoma. Swiss Med Wkly. 142: w13511.
F. Hitz, N. Ketterer, A. Lohri, U. Mey, S. Pederiva, C. Renner, C. Taverna, A. Hartmann, K. Yeow, S. Bodis, E. Zucca. 2011. Diagnosis and treatment of follicular lymphoma. Swiss Med Wkly. 141: w13247.
P. Lang, K. Yeow, A. Nichols, and A. Scheer. 2006. Cellular imaging in drug discovery. Nature Rev Drug Discov. 5(4): 343-356.
A.-M. de Raemy-Schenk, S. Troublé, P. Gaillard, P. Page, J.-P. Gotteland, A. Scheer, P. Lang, and K. Yeow. 2006. A cellular assay for measuring the modulation of glucose production in H4IIE cells. Assay Drug Dev Technol. 4(4): 451-460.
K. Yeow, L. Novo-Perez, P. Gaillard, P. Page, J.-P. Gotteland, A. Scheer, and P. Lang. 2006. A cellular assay for measuring the inhibition of glycogen synthase kinase-3 via the accumulation of beta-catenin in Chinese hamster ovary clone K1 cells. Assay Drug Dev Technol. 4(4): 451-460.
D. Besson, K. Yeow, P. Lang, and A. Scheer. 2004. Using microfluidics in HTS laboratories: current achievements and future challenges. European Pharm Review. Sept: 52-56.
C. Cabane, A. Coldefy, K. Yeow, B. Dérijard. 2004. The p38 pathway regulates Akt both at the protein and transcriptional activation levels during myogenesis. Cell Signaling. 16(12):1405-1415.
D. Besson, K. Yeow, P. Lang, and A. Scheer. HTS and cellular biology at Serono. 2003. Current Drug Discovery. Sept: 29-32
C. Cabane, W. Englaro, K. Yeow, M. Ragno, and B. Dérijard. Regulation of C2C12 myogenic terminal differentiation by MKK3/p38 alpha pathway. Am. J. Physiol. Cell Physiol. 2003. 284(3): C658-66.
K. Yeow, C. Cabane, L. Turchi, G. Ponzio, and B. Dérijard. 2002. Increased MAPK signaling during in vitro muscle wounding. Biochem. Biophys. Res. Comm. 293: 112-119.
L. Turchi, A. Chassot, R. Rezzonico, K. Yeow, A. Loubat, B. Ferrua, G. Lenegrate, JP. Ortonne, and G. Ponzio. 2002. Dynamic characterization of the molecular events during in vitro epidermal wound healing. J. Invest. Dermatol. 119(1): 56-63.
K. Yeow, N. Kishnani, M. Hutton, S. Hawkes, G. Murphy, and D. Edwards. 2002. Sorsby's fundus dystrophy tissue inhibitor of metalloproteinases-3 (TIMP-3) mutants have unimpaired matrix metalloproteinase inhibitory activities, but affect cell adhesion to the extracellular matrix. Matrix Biol. 21(1): 75-88.
JH Qi, Q. Ebrahem, K. Yeow, D. Edwards, P. Fox, and B. Anand-Apte. 2002. Expression of Sorsby's fundus dystrophy mutations in human retinal pigment epithelial cells reduces matrix metalloproteinase inhibition and may promote angiogenesis. J Biol Chem. 277(16): 13394-400.
K. Yeow, B. Phillips, C. Dani, C. Cabane, E. Amri, and B. Dérijard. 2001. Inhibition of myogenesis enables adipogenic trans-differentiation in the C2C12 myogenic cell line. FEBS Lett. 2001. 506(2): 157-62.